Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT05040373

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

Conditions: Hereditary Transthyretin-mediated (hATTR) Amyloidosis, Polyneuropathy

Sex: Female

Healthy volunteers: No

Enrollment: 10

Sponsor: Alnylam Pharmaceuticals

Location: Clinical Trial Site Iowa City Iowa

Summary

The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.

Eligibility Criteria

Inclusion Criteria: * Documentation that the patient was exposed to patisiran-LNP at any point starting from 12 weeks before LMP or at any point during pregnancy * Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis Exclusion Criteria: * There are no exclusion criteria for participation in this program.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05040373). StuddyBuddy aggregates publicly available trial information.